Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells

被引:59
|
作者
Nishizaki, M
Sasaki, J
Fang, BL
Atkinson, EN
Minna, JD
Roth, JA
Ji, L
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Unit 445, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA
[3] Univ Texas, SW Med Ctr, Dept Internal Med & Pharmacol, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75230 USA
关键词
D O I
10.1158/0008-5472.CAN-04-0195
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aberrations of the tumor suppressor genes FHIT and p53 are frequently associated with a wide range of human cancers, including lung cancer. We studied the combined effects of FHIT and p53 proteins on tumor cell proliferation and apoptosis in human non-small cell lung carcinoma (NSCLC) cells in vitro and on tumor growth in animal models by adenoviral vector-mediated cotransfer of wild-type FHIT and p53 genes. We found that the coexpression of FHIT and p53 synergistically inhibited tumor cell proliferation in NSCLC cells in vitro and suppressed the growth of human tumor xenografts in nude mice. Furthermore, we found that this synergistic inhibition of tumor cell growth corresponded with the FHIT-mediated inactivation of MDM2, which thereby blocked the association of MDM2 with p53, thus stabilizing the p53 protein. Our results therefore reveal a novel molecular mechanism consisting of FHIT-mediated tumor suppression and the interaction of FHIT with other cellular components in the pathways regulating p53 activity. These findings show that combination treatment with synergistic tumor-suppressing gene therapy such as Ad-FHIT and Ad-p53 may be an effective therapeutic strategy for NSCLC and other cancers.
引用
收藏
页码:5745 / 5752
页数:8
相关论文
共 50 条
  • [1] mdm2 and p53 overexpression in non-small cell lung carcinomas
    Singh, B
    Li, Y
    Sachdev, R
    Greenebaum, E
    Ford, JG
    LABORATORY INVESTIGATION, 1997, 76 (01) : 1009 - 1009
  • [2] Association of p53 and mdm2 in the development and progression of non-small cell lung cancer
    Javid, Jamsheed
    Mir, Rashid
    Julka, P. K.
    Ray, P. C.
    Saxena, Alpana
    TUMOR BIOLOGY, 2015, 36 (07) : 5425 - 5432
  • [3] p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53
    Christine Wasylyk
    Roberto Salvi
    Manuela Argentini
    Christine Dureuil
    Isabelle Delumeau
    Joseph Abecassis
    Laurent Debussche
    Bohdan Wasylyk
    Oncogene, 1999, 18 : 1921 - 1934
  • [4] p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53
    Wasylyk, C
    Salvi, R
    Argentini, M
    Dureuil, C
    Delumeau, I
    Abecassis, J
    Debussche, L
    Wasylyk, B
    ONCOGENE, 1999, 18 (11) : 1921 - 1934
  • [5] FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer
    Cortinovis, D. L.
    Andriani, F.
    Livio, A.
    Fabbri, A.
    Perrone, F.
    Marcomini, B.
    Pilotti, S.
    Mariani, L.
    Bidoli, P.
    Bajetta, E.
    Roz, L.
    Sozzi, G.
    CURRENT CANCER DRUG TARGETS, 2008, 8 (05) : 342 - 348
  • [6] Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer
    Zheng, Datong
    Chen, Yanping
    Gao, Caijie
    Wei, Yongyue
    Cao, Guochun
    Lu, Nan
    Hou, Yayi
    Jiang, Xiuqin
    Wang, Jianjun
    CANCER BIOLOGY & THERAPY, 2014, 15 (11) : 1542 - 1551
  • [7] Combined Effect of Genetic Polymorphisms in P53, P73, and MDM2 on Non-small Cell Lung Cancer Survival
    Liu, Li
    Wu, Chen
    Wang, Ying
    Zhong, Rong
    Duan, Shengyu
    Wei, Sheng
    Lin, Songyi
    Zhang, Xinyu
    Tan, Wen
    Yu, Dianke
    Nie, Shaofa
    Miao, Xiaoping
    Lin, Dongxin
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (11) : 1793 - 1800
  • [8] Inactivation of both FHIT and p53 cooperate in deregulating proliferation related pathways in lung cancer
    Andriani, Francesca
    Roz, Elena
    Caserini, Roberto
    Conte, Davide
    Sozzi, Gabriella
    Roz, Luca
    CANCER RESEARCH, 2009, 69
  • [9] MDM2 inhibitors to reactivate p53 in human cancer
    Vassilev, L.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S6 - S6
  • [10] Roles of Fhit and p53 in Taiwanese surgically treated non-small-cell lung cancers
    Y-L Chang
    C-T Wu
    J-Y Shih
    Y-C Lee
    British Journal of Cancer, 2003, 89 : 320 - 326